EICHOR
● Recruiting
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Condition: Head and Neck Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
About this study
The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
This description comes directly from the study's public registry record.
Talk to the study team
Ximei Zhang, Dr. · +86-22-23340123 · xiangrikuigirl@126.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Sichuan Cancer Hosiptal | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.